文献速递肿瘤 PET/CT核素与放射性配体治疗

靶向人激肽释放酶2的放射性标记抗体在转移性去势抵抗性前列腺癌患者中的生物分布与药代动力学0期研究

A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer.
PubMed 文献 · J Nucl Med · 2024-07-01

这项首次人体0期试验用111In标记的抗hK2单克隆抗体[111In]-DOTA-h11B6在22例进展性mCRPC患者中评估生物分布与药代动力学。给药后6–8天抗体在已知mCRPC病灶可见聚集,其他器官摄取有限;血清清除、生物分布与肿瘤靶向不依赖抗体总量(2或10 mg)。作者认为数据支持hK2作为显像靶点的可行性及hK2靶向药物作为潜在疗法的可行性。

要点

  • 22例进展性mCRPC患者接受单次2 mg [111In]-DOTA-h11B6(185 MBq 111In)输注。
  • 给药后6–8天[111In]-DOTA-h11B6在已知mCRPC病灶可见聚集,其他器官摄取有限。
  • 血清清除、生物分布与肿瘤靶向不依赖抗体总量(2或10 mg)。

核心结论

  • 作者认为该首次人体研究证明肿瘤相关hK2可被识别,h11B6抗体选择性聚集于mCRPC转移灶且清除动力学不依赖抗体总量。
  • 作者认为数据支持hK2作为显像靶点的可行性,以及hK2靶向药物作为mCRPC患者潜在疗法的可行性。

研究设计与样本

  • 首次人体0期试验,使用111In标记的抗hK2单克隆抗体[111In]-DOTA-h11B6。
  • 22例进展性mCRPC患者接受单次2 mg [111In]-DOTA-h11B6(185 MBq 111In)输注,联合或不联合8 mg未标记h11B6以评估抗体质量效应。
  • 进行序贯显像与系列血样采集以测定生物分布、剂量学、血清放射性与药代动力学。
  • 安全性评估时间为[111In]-DOTA-h11B6给药后2周随访期内。

主要发现

  • 22例接受[111In]-DOTA-h11B6的患者纳入分析。
  • 给药后6–8天,[111In]-DOTA-h11B6在已知mCRPC病灶可见聚集,其他器官摄取有限。
  • 发生2例与治疗无关的治疗中出现的不良事件,其中1例肿瘤相关出血导致提前终止研究。
  • 血清清除、生物分布与肿瘤靶向不依赖抗体总量(2或10 mg)。

关键数值与推荐

  • 给药方案为单次输注2 mg [111In]-DOTA-h11B6(185 MBq 111In),联合或不联合8 mg未标记h11B6。
  • 安全性评估窗口为给药后2周随访期。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite the inclusion of multiple agents within the prostate cancer treatment landscape, new treatment options are needed to address the unmet need for patients with metastatic castration-resistant prostate cancer (mCRPC). Although prostate-specific membrane antigen is the only cell-surface target to yield clinical benefit in men with advanced prostate cancer, additional targets may further advance targeted immune, cytotoxic, radiopharmaceutical, and other tumor-directed therapies for these patients. Human kallikrein 2 (hK2) is a novel prostate-specific target with little to no expression in nonprostate tissues. This first-in-human phase 0 trial uses an 111In-radiolabeled anti-hK2 monoclonal antibody, [111In]-DOTA-h11B6, to credential hK2 as a potential target for prostate cancer treatment. Methods: Participants with progressive mCRPC received a single infusion of 2 mg of [111In]-DOTA-h11B6 (185 MBq of 111In), with or without 8 mg of unlabeled h11B6 to assess antibody mass effects. Sequential imaging and serial blood samples were collected to determine [111In]-DOTA-h11B6 biodistribution, dosimetry, serum radioactivity, and pharmacokinetics. Safety was assessed within a 2-wk follow-up period from the time of [111In]-DOTA-h11B6 administration. Results: Twenty-two participants received [111In]-DOTA-h11B6 and are included in this analysis. Within 6-8 d of administration, [111In]-DOTA-h11B6 visibly accumulated in known mCRPC lesions, with limited uptake in other organs. Two treatment-emergent adverse events unrelated to treatment occurred, including tumor-related bleeding in 1 patient, which led to early study discontinuation. Serum clearance, biodistribution, and tumor targeting were independent of total antibody mass (2 or 10 mg). Conclusion: This first-in-human study demonstrates that tumor-associated hK2 can be identified and targeted using h11B6 as a platform as the h11B6 antibody selectively accumulated in mCRPC metastases with mass-independent clearance kinetics. These data support the feasibility of hK2 as a target for imaging and hK2-directed agents as potential therapies in patients with mCRPC.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Pandit-Taskar N, O'Donoghue JA, Chetty D, et al. A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2024. PMID: 38782459. doi:10.2967/jnumed.124.267416

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。